The dispute over who invented CRISPR-Cas9 (CRISPR), a gene-editing technology awarded the 2020 Nobel Prize in Chemistry, has been one of the most closely watched legal battles in the world of ...

Personalized CRISPR cures for children born with rare genetic diseases are now a step closer to being more widely available.

New research has found a novel target with therapeutic potential for metastatic eye melanoma—an aggressive eye cancer—with implications for a range of other cancers.

Crispr investors have had a year to put aside so far, with the stock down 25%. Read more on CRSP's execution risks, high valuation, and speculative pipeline raise concerns.

A new study reveals how CRISPR gene editing could potentially eradicate Down syndrome.

In a decision underscoring the distinct standards governing enablement under §§ 102 and 112, the US Court of Appeals for the Federal Circuit affirmed the Patent Trial & Appeal Board’s finding ...

In a precedential decision issued on June 11, 2025, the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed two Patent Trial and Appeal Board (PTAB) inter partes review (IPR) decisions ...

The study generated approximately 1,300 CRISPR lines to influence tomato traits, including flavor, nutrient uptake, and pathogen response.

"Our work has direct applications for powering the DC-biased superconducting logic and quantum circuits and thus readily enables their scaled-up operation, thereby has the most relevant practical ...

Stanford researchers have developed a technology that delivers RNA to damaged neurons and stimulates regrowth – paving the way for potential treatments for neurodegenerative diseases like ...

A favorable appeals court ruling repositioned a coalition of universities and Nobel laureates to win credit for inventing a breakthrough CRISPR gene-editing technology and lucrative rights to a US ...

CRISPR Therapeutics stock is down more than 80% from the peak it reached in 2021. The first drug from CRISPR Therapeutics launched early last year, but annualized sales are still less than $60 ...